Steven Brem, M.D.
Affiliations: | Neurosurgery | Hospital of the University of Pennsylvania |
Area:
GBM, 14-3-zeta, angiogenesis, meningiomaWebsite:
http://www.med.upenn.edu/apps/faculty/index.php/g275/p8483396Google:
"Steven Brem"Collaborators
Sign in to add collaborator| National Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Galbraith K, Kumar A, Abdullah KG, et al. (2020) Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. Journal of Neuropathology and Experimental Neurology |
| Henderson F, Brem S, O'Rourke DM, et al. (2020) F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling. Neuro-Oncology Practice. 7: 152-157 |
| Akbari H, Rathore S, Bakas S, et al. (2020) Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Cancer |
| Huang M, Zhang D, Wu JY, et al. (2020) Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Science Translational Medicine. 12 |
| Henderson F, Brem S, Hussain J, et al. (2020) Second window indocyanine green localizes CNS lymphoma in real time in the operating room: report of two cases. British Journal of Neurosurgery. 1-5 |
| Henderson F, Abdullah KG, Verma R, et al. (2020) Tractography and the connectome in neurosurgical treatment of gliomas: the premise, the progress, and the potential. Neurosurgical Focus. 48: E6 |
| Reardon DA, Brem S, Desai AS, et al. (2020) INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal of Clinical Oncology. 38: 2514-2514 |
| Sampson JH, Achrol A, Aghi MK, et al. (2020) MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. Journal of Clinical Oncology. 38: 2513-2513 |
| Bagley SJ, Nabavizadeh SA, Till J, et al. (2020) A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 38: 2508-2508 |
| Skolnik J, Reardon D, Brem S, et al. (2020) P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM) Journal For Immunotherapy of Cancer. 8: A8.1-A8 |